Neurobiology of Aging 96 (2020) 176–183

Contents lists available at ScienceDirect

Neurobiology of Aging

journal homepage: www.elsevier.com/locate/neuaging

Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI

Sheelakumari Raghavan[a], Scott A. Przybelski[b], Robert I. Reid[c], Jonathan Graff-Radford[d], Timothy G. Lesnick[b], Samantha M. Zuk[a], David S. Knopman[d], Mary M. Machulda[e], Michelle M. Mielke[b,d], Ronald C. Petersen[d], Clifford R. Jack Jr[a], Prashanthi Vemuri[a,*]

[a] Department of Radiology, Mayo Clinic, Rochester, MN, USA
[b] Health Sciences Research, Mayo Clinic, Rochester, MN, USA
[c] Information Technology, Mayo Clinic, Rochester, MN, USA
[d] Department of Neurology, Mayo Clinic, Rochester, MN, USA
[e] Department of Psychology, Mayo Clinic, Rochester, MN, USA

ARTICLE INFO

Article history:
Received 30 April 2020
Received in revised form 25 August 2020
Accepted 1 September 2020
Available online 8 September 2020

Keywords:
Diffusion tensor imaging
Mild cognitive impairment
Cerebrovascular disease
Genu of the corpus callosum

ABSTRACT

Our goal was to evaluate the utility of diffusion tensor imaging (DTI) for predicting future cognitive decline in mild cognitive impairment (MCI) in conjunction with Alzheimer's disease (AD) biomarkers (amyloid positron emission tomography and AD signature neurodegeneration) in 132 MCI individuals ≥60 year old with structural magnetic resonance imaging, DTI, amyloid positron emission tomography, and at least one clinical follow-up. We used mixed-effect models to evaluate the prognostic ability of fractional anisotropy of the genu of the corpus callosum (FA-Genu), as a cerebrovascular disease marker, for predicting cognitive decline along with AD biomarkers. We contrasted the value of white matter hyperintensities, a traditional cerebrovascular disease marker as well as FA in the hippocampal cingulum bundle with the FA-Genu models. FA-Genu significantly predicted cognitive decline even after accounting for AD biomarkers. WMH was not associated with cognitive decline in the model with both WMH and FA-Genu. DTI specifically FA-Genu provides unique complementary information to AD biomarkers and has significant utility for prediction of cognitive decline in MCI.

1. Introduction

Mild cognitive impairment (MCI) is often a prodrome of dementia (Petersen, 2009) with a progression rate of 10%–15% per year (Bruscoli and Lovestone, 2004; Petersen et al., 2001), and many of those with MCI who progress to Alzheimer's disease (AD) dementia have elevated levels of amyloid beta (Quigley, Colloby and O'Brien, 2011). Because a significant proportion of variability in progression to dementia from MCI is not explained by brain amyloid beta levels, there is a need for additional biomarkers to aid in the prediction of future cognitive decline in MCI.

Diffusion tensor imaging (DTI) is a promising marker for cerebrovascular disease (CVD) (Tu et al., 2017; Williams et al., 2017). Studies have shown that reduction of fractional anisotropy (FA) or directionality and increase in overall mean diffusivity (MD) are associated with cognitive decline (Croall et al., 2017; Tuladhar et al., 2015). We recently reported that the FA of the genu of the corpus callosum (FA-Genu) is a useful biomarker of CVD because the loss of microstructural integrity in the genu was associated with worsening of systemic vascular health and cerebrovascular injury even after accounting for AD pathologies (Vemuri et al., 2018). This was supported by several studies that have found disconnection of the white matter (WM) tracts in MCI in the context of CVD (Catani and ffytche, 2005; O'Sullivan et al., 2001). Our primary aim was to test if poor WM microstructural health, as captured by FA-Genu, was predictive of faster cognitive decline and to evaluate its clinical utility in the presence of AD biomarkers (amyloid and neurodegeneration).

Using DTI, we investigated the interrelationships between FA-Genu, amyloid pathology, neurodegeneration (cortical thickness in AD signature regions), and cognitive decline among participants with MCI, aged 60 years and older, and enrolled in the population-based Mayo Clinic Study of Aging (MCSA). In addition, we also compared the effectiveness of DTI measures from a different region, FA in the hippocampal cingulum bundle (FA-HCB), a tract that has been known to be vulnerable to AD pathology.

* Corresponding author at: Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA. Tel.: +1 507 538 0761fax: +1 507 284 9778.
E-mail address: vemuri.prashanthi@mayo.edu (P. Vemuri).

0197-4580/$ – see front matter © 2020 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.neurobiolaging.2020.09.005

2. Materials and methods

2.1. Selection of participants

The MCSA was designed to investigate the epidemiology of MCI and risk factors for MCI and dementia among the residents of Olmsted County, Minnesota. The MCSA sample population was enumerated from the Olmsted County population using the Rochester Epidemiology Project medical records-linkage system (Rocca et al., 2012; St Sauver et al., 2012). The participants with MCI were diagnosed based on the published consensus criteria (Petersen et al., 2010) that were described previously. In the current analyses, we included participants ≥60 years of age who had a diagnosis of MCI at the time of their structural magnetic resonance imaging (MRI), DTI, fluid-attenuated inversion recovery (FLAIR)-MRI, and amyloid positron emission tomography (PET) scans that had sufficient quality and had detailed neuropsychology evaluation at the imaging visit, and at least one clinical follow-up.

Standard protocol approvals, registrations, and patient consents

The study was approved by the Mayo Clinic and Olmsted Medical Center institutional review board, and written informed consent was obtained from all participants.

2.2. Imaging biomarkers

All MRI scans were obtained on a 3T GE scanner with an eight-channel phase array coil (GE, Milwaukee, WI).

2.2.1. DTI acquisition and processing

DTI acquisition was performed using a single-shot echo-planar imaging sequence with an isotropic resolution of 2.7 mm. The DTI data consisted of 46 images for each set with 41 diffusion-encoding gradient directions (b = 1000 s/mm2) and 5 nondiffusion-weighted images (b = 0 s/mm2). The diffusion data were preprocessed using the in-house developed pipeline. Briefly, the images were skull stripped (Reid et al., 2018), denoised (Veraart et al., 2016), corrected for head motion and eddy current distortion (Andersson et al., 2016), Gibbs ringing (Kellner et al., 2016), and then Rician noise bias correction was performed (Koay et al., 2009). Diffusion tensors were then fitted by nonlinearly minimizing the squared residuals (Garyfallidis et al., 2014), and FA and MD maps were calculated from the tensors. Advanced normalization tools—symmetric normalization (Avants et al., 2011) was used to nonlinearly register the FA image of the JHU "Eve" atlas to each participant's FA image (Oishi et al., 2009), and the median values of FA in each region were obtained. The atlas was slightly modified by fusing the left and right portions of structures spanning the left-right midplane, such as the genu and pons.

2.2.2. Neurodegeneration assessment from structural scans

The cortical thickness measurements were performed from MPRAGE scans using the FreeSurfer, version v5.3, and estimated the average cortical thickness of AD signature regions including the entorhinal cortex, inferior temporal, middle temporal, and fusiform gyrus. A derived single measure was used as the surrogate marker of neurodegeneration (Schwarz et al., 2016).

2.2.3. Amyloid assessment from PET scans

The detailed descriptions of acquisition, processing, and summary measure calculation for amyloid PET scans were published previously (Jack et al., 2017). A cortical global Pittsburgh compound B PET (PiB-PET) standardized uptake value ratio was computed by calculating the median uptake over voxels in the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/precuneus region of interest values for each participant normalized by the cerebellar crus gray matter of the in-house atlas modified from Lopresti et al. (Lopresti et al., 2005) and used as a global amyloid load measure.

2.2.4. Cerebrovascular pathology assessment from FLAIR scans

The acquisition and analysis of FLAIR-MRI images on the study participants were described in detail by Graff-Radford et al. (Graff-Radford et al., 2019). Briefly, all participants' MPRAGE and FLAIR images were coregistered to template space using Statistical Parametric Mapping. Then FLAIR images were masked using the segmented WM mask from the MPRAGE image to remove the nonbrain tissue and voxels other than white matter hyperintensities (WMH). WMH voxels on FLAIR images were segmented using semiautomated clustering technique as described by Graff-Radford et al. (Graff-Radford et al., 2019). These custom-made masks were further visually inspected and manually edited by the trained analysts to exclude the artifacts from the WMH volume. We used the WMH fraction as ratio of WMH to the total intracranial volume as our outcome measure.

2.3. Cognitive performance measures

A detailed neuropsychological evaluation was performed on all MCSA participants as described previously (Petersen et al., 2010; Roberts et al., 2008). We assessed 4 cognitive domains using 9 tests: executive (Trail Making Test Part B and Wechsler Adult Intelligence Scale—Revised (WAIS-R) Digit Symbol), language (Boston Naming Test and category fluency), Memory (Wechsler Memory Scale—Revised (WMS-R) Logical Memory-II (delayed recall), WMS-R Visual Reproduction-II (delayed recall), Auditory Learning Verbal Test delayed recall), and Visuospatial performance (WAIS-R Picture Completion and WAIS-R Block Design). In this study, we used a global cognitive function standard score that was derived from the z-transformation of the average of the 4 standardized cognitive domain scores: memory, language, attention/executive, and visuospatial function (Vemuri et al., 2014).

2.4. Statistical analysis

All statistical analyses were performed using R statistical software, version 3.4.2 (R Foundation).

2.4.1. Evaluation of the DTI biomarker and education/occupation variables for predicting global cognition

We examined the effect of each of the DTI markers (FA-Genu in the primary models and FA-HCB in the sensitivity analyses) and AD markers on longitudinal global cognitive performance using linear mixed-effect models. We fit 3 separate linear mixed-effect models for the DTI marker with global cognition as the dependent variable, and follow-up time, age, sex, education/occupation, and various imaging biomarkers as fixed predictors. In the first model, we only used the DTI marker, in the second model, the DTI marker in conjunction with amyloid, and in the third model, the DTI marker in conjunction with amyloid and neurodegeneration. In these models, we considered all the main effects as well as the interactions of interest with time. We also tested for interactions of age, sex, and education/occupation with the DTI marker. The models were fit with random intercepts and slopes. We did not test for three-way interaction because of limited power. Among the three separate models for our predictors of interest, we compared the goodness of fit using Akaike information criteria (AIC). Lower AIC suggests greater prediction of variance in the data. The nonsignificant terms were removed from the model one at time, accounting for nested effects, until the final parsimonious models were reached. All models were tested and controlled for within-subject autocorrelation of the repeated measures.

The final parsimonious model included all main effects as well as all significant two-way interactions of potential predictors with

time. We tested specifically for interactions of the DTI imaging biomarker, other imaging biomarkers (PiB and cortical thickness), education/occupation, age, and time. The global amyloid values used in the model were log transformed. A significant interaction of the predictor with time would estimate the rate of change of global cognition over time based on the values of predictor variables.

2.4.2. Assessing the utility of the DTI biomarker in conjunction with WMH

We estimated the added value of the DTI marker for prediction of longitudinal cognition in MCI after accounting for WMH. The WMH was analyzed as percentage of total intracranial volume in the model, and values were log transformed. We fitted linear mixed-effect models with global cognition as the outcome variable and with age and time as fixed effects. The final parsimonious model included all significant interactions of imaging biomarkers with time, main effects nested within those interactions, and other significant main effects.

3. Results

The demographics, Apolipoprotein E4 status, intellectual enrichment variables, cognitive measures, vascular and AD biomarker values are provided in Table 1. As depicted in Table 1, out of 132 participants with MCI, 51 (39%) were Alzheimer's disease positive and 73 (55%) were amyloid-positive. Participants had a mean education level of 13.8 years and an education/occupation mean score of 11.7. The baseline global cognition z-scores were normally distributed among the participants. The mean follow-up time was 4.05 years (standard deviation).

3.1. FA-Genu for prediction of longitudinal cognitive decline

The results of the 3 linear mixed-effect models: 1) FA-Genu alone; 2) FA-Genu and PiB combined; and 3) FA-Genu, PiB, and cortical thickness are presented in Table 2. In all 3 models with FA-Genu, higher education/occupation scores were associated with better baseline cognitive performance ($p < 0.01$). In the model of FA-Genu alone, age was a predictor of baseline cognitive performance and had a faster rate of cognitive decline. Sex was not a significant predictor of cognition in any of the models and dropped out from further analysis. In model 3, all 3 biomarkers (FA-Genu, PiB, and cortical thickness) significantly predicted the rate of cognitive decline ($p < 0.05$). The significant interaction between FA-Genu and time indicated that participants with MCI with higher FA declined more slowly over time. In the third model with all 3 imaging predictors, the AIC was lower providing evidence that including all imaging predictors improved prediction of longitudinal cognition. A plot of predicted global cognition categorized by the imaging biomarkers and a spaghetti plot of global cognition as a function of age are shown in Fig. 1. In the left panel, we illustrated the predicted cognition z-score trajectories by FA-Genu and PiB values maintaining education/occupation as constant. We found that the participants with low FA-Genu and high PiB declined fastest among the groups.

Table 1
Characteristics table of participants with MCI with the mean (SD) listed for the continuous variables and count (%) for the categorical variables

All participants n = 132	
Demographics	
Age, y	77.3 (7.4)
Males, no. (%)	78 (59%)
APOE, no. (%)	51 (39%)
Intellectual enrichment	
Education/occupation	11.7 (2.7)
Education, y	13.8 (2.9)
Cognitive measures	
MMSE	25.8 (1.8)
Global z-score	−1.58 (0.97)
Memory z-score	−1.56 (1.06)
Language z-score	−1.29 (1.20)
Attention z-score	−1.40 (1.44)
Visual spatial z-score	−0.79 (1.06)
PiB, neurodegeneration, and follow-up	
PiB SUVr	1.83 (0.55)
PiB+, no. (%)	73 (55%)
Neurodegeneration, mm	2.73 (0.21)
Neurodegeneration+, no. (%)	93 (72%)
Follow-up, y	4.05 (2.16)
Dementia progression, no. (%)	19 (14%)
Vascular markers	
Cardio metabolic condition	2.71 (1.47)
FA-Genu	0.57 (0.06)
FA-HCB	0.45 (0.04)
WMH/total intracranial volume	0.014 (0.011)

Key: FA-Genu, fractional anisotropy of the genu of the corpus callosum; FA-HCB, FA in the hippocampal cingulum bundle; MCI, mild cognitive impairment; PiB, Pittsburgh compound B; SD, standard deviation.

3.2. FA-HCB for prediction of longitudinal cognitive decline

The results of the linear mixed-effect models of FA-HCB, which were conducted as part of our sensitivity analyses, are presented in Table 3. In all 3 models of FA-HCB, education/occupation was an important component as in the FA-Genu models. Older age significantly predicted faster rate of annual cognitive decline in models with FA-HCB alone and model 2 (FA-HCB+ with PiB). FA-HCB had significant interactions with sex and PiB in model 2. FA-HCB predicted cognitive decline (interaction with time) only in models 1 and 2. In the third model (FA-HCB, PiB, and cortical thickness), only PiB and cortical thickness but not FA-HCB significantly predicted the longitudinal rate of cognitive decline. However, there were significant interactions of FA-HCB with PiB and FA-HCB with baseline age in model 3. The predicted cognition z-score trajectories by the FA-HCB and PiB levels maintaining education/occupation as constant are illustrated in Fig. 2. We found that although the participants with low FA-HCB and high PiB declined fastest among the groups, the FA-HCB interacts with PiB. The comparison of these results with FA-Genu suggests that FA-Genu is a better DTI marker than FA-HCB which may be in the pathway of the AD biomarker cascade.

3.3. DTI association with WMH

The linear mixed model results with both the DTI marker and WMH after adjusting for age, time from baseline, and education/occupation score results in a simplified model as shown in Table 4 because WMH drops out due to nonsignificant effect. Therefore, only the DTI marker, FA-Genu ($p = 0.01$) but not WMH, significantly predicted longitudinal cognition.

4. Discussion

The present study aimed to examine the utility of DTI imaging for predicting cognitive decline in individuals with MCI over 60 years of age in conjunction with brain amyloidosis and neurodegeneration. The major findings of this population-based study are as follows:(1) FA-Genu was significantly associated with cognitive rate of decline in individuals with MCI even after adjusting for information provided by amyloid deposition and neurodegeneration; (2) FA-HCB was not significantly associated with the cognitive rate of decline after adjusting for amyloid deposition and neurodegeneration; and (3) only FA-Genu and not

Table 2
Mixed models evaluating the utility of the genu FA (FA-Genu) in predicting cognitive performance

Models	Variables	Coefficient (s.e.)	*p*-value
FA-Genu	Intercept	−2.118 (1.625)	0.19
AIC	Time	−0.068 (0.267)	0.80
973.9088	Baseline age	−0.028 (0.013)	0.04
	Education/occupation	0.097 (0.032)	0.003
	FA-Genu	2.730 (1.726)	0.12
	FA-Genu × time	0.748 (0.289)	0.01
	Baseline age × time	−0.006 (0.002)	0.002
FA-Genu+ PiB	Intercept	−4.050 (1.003)	<0.001
AIC	Time	−0.517 (0.152)	<0.001
940.3542	Education/occupation	0.077 (0.030)	0.011
	FA-Genu	3.607 (1.557)	0.022
	PiB	−0.803 (0.306)	0.01
	FA-Genu × time	0.904 (0.255)	<0.001
	PiB × time	−0.246 (0.049)	<0.001
FA-Genu+ PiB + cortical thickness	Intercept	−5.543 (1.401)	<0.001
AIC	Time	−1.193 (0.222)	<0.001
900.9365	Education/occupation	0.090 (0.029)	0.003
	FA-Genu	2.833 (1.605)	0.08
	PiB	−0.738 (0.315)	0.021
	Cortical thickness	0.650 (0.452)	0.15
	FA-Genu × time	0.528 (0.268)	0.049
	PiB × time	−0.164 (0.052)	0.002
	Cortical thickness × time	0.307 (0.076)	<0.001

Key: AIC, Akaike information criteria; FA, fractional anisotropy; PiB, Pittsburgh compound B.

WMH was associated with cognitive decline when the model contained both WMH and FA-Genu.

DTI is a promising biomarker for studying the integrity of WM in MCI. Here, we found a significant association between WM structural integrity, measured by FA-Genu, and cognitive decline among participants with MCI. Importantly, this association was independent of PiB and cortical thickness, supporting its utility as a biomarker in MCI.

The well-defined mechanism of cognitive impairment is that of cortical disconnection (Catani and ffytche, 2005; Lamar et al., 2008), which has been suggested to be influenced by CVD (Croall et al., 2017; Tu et al., 2017; Tuladhar et al., 2015). The CC is the largest WM tract in the brain and plays a crucial role in interhemispheric communication. The loss of these connections can disrupt connectivity of several cortical regions and recognized in age-related cognitive declines (O'Sullivan et al., 2001). These WM changes can therefore be the underlying cause of widespread cognitive impairment in CVD characterized by predominant dysfunction in attention, psychomotor speed, and executive function.

Several lines of evidence indicate the relationship between frontal lobe damage and vascular disease (Knopman et al., 2015; Tullberg et al., 2004), suggesting that the genu of the CC is the most susceptible region to vascular disease effects. Furthermore, FA-Genu was found to capture early changes due to systemic vascular health which lends itself as a useful CVD biomarker in MCI (Vemuri et al., 2018). As reported in prior studies (Croall et al., 2017; Vemuri et al., 2018), FA is a sensitive marker of CVD. We did not



Fig. 1. (Left) The predicted global cognitive trajectories for a 78-year-old participant by time from baseline for a given FA-Genu and amyloid level. In the graph, low and high were defined by 25th and 75th percentiles. (Right) The spaghetti plot of global cognition as a function of age. Abbreviations: FA-Genu, fractional anisotropy of the genu of the corpus callosum.

Table 3
Mixed models evaluating the utility of the hippocampal cingulum bundle FA (FA-HCB) in predicting cognitive performance

Models	Variables	Coefficient (s.e.)	*p*-value
FA-HCB	Intercept	8.694 (5.222)	0.10
AIC	Time	0.008 (0.260	0.98
968.5585	Baseline age	−0.029 (0.013)	0.028
	Education/occupation	−0.844 (0.429)	0.051
	FA-HCB	−20.270 (11.221)	0.073
	FA-HCB × time	1.002 (0.413)	0.016
	FA-HCB × education/occupation	2.083 (0.946)	0.03
	Baseline age × time	−0.008 (0.002)	<0.001
FA-HCB + PiB	Intercept	−2.306 (2.795)	0.41
AIC	Time	−0.046 (0.243)	0.85
949.1162	Baseline age	−0.021 (0.014)	0.12
	Male	−5.078 (2.156)	0.02
	Education/occupation	0.078 (0.031)	0.014
	FA-HCB	4.021 (5.477)	0.46
	PiB	6.545 (3.458)	0.061
	FA-HCB × time	0.823 (0.388)	0.034
	FA-HCB × male	11.395 (4.773)	0.019
	FA-HCB × PiB	−15.960 (7.759)	0.042
	PiB × time	−0.199 (0.056)	<0.001
	Baseline age × time	−0.005 (0.002)	0.026
FA-HCB+ PiB + cortical thickness	Intercept	21.230 (11.670	0.07
AIC	Time	−1.074 (0.215)	<0.001
899.9934	Baseline age	−0.412 (0.163)	0.013
	Education/occupation	0.089 (0.030)	0.003
	FA-HCB	−49.805 (25.514)	0.053
	PiB	9.937 (3.896)	0.012
	Cortical thickness	0.252 (0.476)	0.60
	FA-HCB × baseline age	0.868 (0.360)	0.017
	FA-HCB × PiB	−23.645 (8.760)	0.008
	PiB × time	−0.155 (0.054)	0.004
	Cortical thickness × time	0.371 (0.072)	<0.001
	FA-HCB × time	0.568 (0.383)	0.14

Key: AIC, Akaike information criteria; FA, fractional anisotropy; PiB, Pittsburgh compound B.

investigate MD here because it measures overall water diffusion and may be less specific to subtle microstructure WM abnormalities due to cerebrospinal fluid contamination (CSFC). The contribution of partial volume effect due to CSFC has been found more problematic in brain structures with close proximity of ventricles such as the fornix and the genu of CC (Concha et al., 2005; Jones and Cercignani, 2010). In addition, a greater CSFC for the diffusivity measurements than FA was demonstrated previously in the fornix of the older adults (Metzler-Baddeley et al., 2012) and genu of CC in the participants with MCI (Berlot et al., 2014).

Multiple studies have documented CC atrophy in clinically diagnosed MCI and AD dementia (Elahi et al., 2015; L. Wang et al., 2009), and some have reported predominant atrophy in the anterior part (Thomann et al., 2006; Zhu et al., 2012). However, the CC changes in MCI across studies have not been consistent (Thomann et al., 2006; H. Wang and Su, 2006). A previous Rotterdam Study in patients with MCI with CVD found microstructural damage in the genu, internal and external capsule, and periventricular WM, but in those without CVD, deterioration was found along the hippocampal tract (Papma et al., 2014), suggesting that the anterior changes may



Fig. 2. The predicted global cognitive trajectories for a 78-year-old participant by time from baseline for a given FA-HCB and amyloid level. In the graph, low and high were defined by 25th and 75th percentiles. Abbreviations: FA-HCB, fractional anisotropy in the hippocampal cingulum bundle.

Table 4
Mixed models evaluating the utility of the genu FA (FA-Genu) in conjunction with WMH in predicting cognitive performance

Models	Variables	Coefficient	S.E	*p*-value
FA-Genu + WMH	Intercept	−2.462	1.694	0.147
AIC 995.102	Time	−0.110	0.285	0.699
	Baseline age	−0.026	0.014	0.066
	Education/occupation	0.103	0.034	0.003
	FA-Genu	2.231	1.866	0.234
	WMH	−0.091	0.136	0.506
	FA-Genu × time	0.727	0.296	0.014
	Baseline age × time	−0.006	0.002	0.011
	WMH × time	−0.011	0.018	0.543
	Educ/occ × time	−0.005	0.005	0.372

Key: AIC, Akaike information criteria; FA, fractional anisotropy.

be more specific to CVD. A consistent DTI change in the genu was also demonstrated in patients with subcortical vascular dementia (Chen et al., 2009) further supporting our use of FA-Genu.

One would argue against using a specific tract instead of global DTI measures. For example, data from the participants of Atherosclerosis Risk in Communities Study showed an association between overall DTI measures with cognitive decline, incident MCI, dementia, and mortality longitudinally (Power et al., 2019). The same was true in a recent Harvard Aging Brain Study where a global FA measure significantly predicted longitudinal cognitive decline even after adjusting for amyloid level (Rabin et al., 2019). However, we specifically chose FA-Genu because other limbic tracts such as the hippocampal cingulum and fornix have been observed in preclinical AD (Chao et al., 2013; Gold et al., 2014; Jacobs et al., 2018; Rieckmann et al., 2016), suggesting its relationship with amyloid pathology. The sensitivity analyses we conducted in Table 3 support associations between HCB and AD pathophysiology. With amyloidosis and neurodegeneration in the model (model 3), we did not find any significant interaction between FA-HCB and time. The observed interaction between FA-HCB and PiB suggests that HCB may be a part of the AD pathway (Jacobs et al., 2018). More importantly, measuring FA-Genu we are able to capture the independent effect of vascular disease. We also performed sensitivity analyses using cognitive subdomains which indicated variability in associations across the domains as expected due to the heterogeneity seen in etiology of MCI (supplementary table).

Evaluating conventional CVD measures like WMH is important to determine the utility of DTI over traditional measures. Although the modifiable cardiovascular risk factors such as hypertension, diabetes, and body mass index are identified in association with WM integrity declines (Wassenaar et al., 2019), measurement of WMH provides the extent of CVD damage. Although WMH alone was predictive of cognitive decline, we found that WMH was not predictive of cognitive decline in the combined linear mixed model with FA-Genu in the model. These findings support the independent utility of FA-Genu for predicting cognitive performance in patients with MCI aged 60 years and older as it may be able to capture more subtle microstructural damage.

The present study has some strengths and limitations. A major strength is the availability of amyloid PET, MRI, and longitudinal cognitive outcomes in a population-based sample. There are several limitations. We relied on simple and robust measures (genu FA and global cognitive z-score) to study the relationship between DTI metrics and longitudinal cognitive decline after accounting for AD biomarkers. The small sample size to detect subtle effects such as those with WMH may limit the findings of the study. Highly educated individuals in the cohort may have an influence on the generalizability of this study. There is some regional variability in the etiology of WMH as shown recently (Al-Janabi et al., 2018; Graff-Radford et al., 2019; Weaver et al., 2019), but we only considered global WMH in this work and not regional WMH because global WMH is the typically used CVD measure in most aging and dementia studies. In addition, newer biophysical modeling methods that may allow for robust metrics such as neurite orientation dispersion and density imaging and free water elimination may be helpful in providing better metrics of WM integrity and will be part of future investigations. In contrast to DTI, these techniques could reliably account for the partial volume effects by CSFC and therefore provide better sensitivity even in the asymptomatic/preclinical stages.

5. Conclusions

Our findings illustrate the complex interplay between brain structure, brain function, and cognitive decline in MCI. Greater DTI measures (indicator of brain reserve or structure) predicted slower decline over time. Accounting for brain structure (neurodegeneration and WM integrity) and amyloid strengthens our findings. DTI has significant utility for prediction of cognitive decline in MCI from a population-based sample and will provide complementary information to AD biomarkers.

Disclosure statement

The authors report no conflicts of interest relevant to this manuscript. Dr. Knopman reported serving on a data safety monitoring board for the DIAN study, serving on a Data Safety monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation, and serving as an investigator in a clinical trials sponsored by Lilly Pharmaceuticals and the University of Southern California, and receiving research support from the National Institutes of Health (NIH) outside the submitted work. Dr. Graff-Radford reported receiving research support from the National Institute on Aging outside the submitted work. Dr. Mielke reported receiving research support from the NIH, Department of Defense, and unrestricted research grants from Biogen outside the submitted work. Dr. Jack reported consulting for Eli Lilly, serving on an independent data monitoring board for Roche, and serving as a speaker for Eisai but receives no personal compensation from any commercial entity; he also reported receiving research support from the NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Petersen reported receiving consulting fees from Hoffman-La Roche Inc, Merck Inc, Genentech Inc, Biogen Inc, GE Healthcare, and Eisai Inc. outside the submitted work. Dr. Vemuri reported receiving grants from the NIH during the conduct of the study.

CRediT authorship contribution statement

Sheelakumari Raghavan: Conceptualization, Methodology, Investigation, Formal analysis, Writing - original draft. **Scott A. Przybelski:** Investigation, Formal analysis, Writing - original draft. **Robert I. Reid:** Investigation, Formal analysis. **Jonathan Graff-Radford:** Investigation, Formal analysis. **Timothy G. Lesnick:** Investigation, Formal analysis, Writing - original draft. **Samantha M. Zuk:** Investigation, Formal analysis. **David S. Knopman:** Investigation, Formal analysis. **Mary M. Machulda:** Investigation, Formal analysis. **Michelle M. Mielke:** Investigation, Formal analysis. **Ronald C. Petersen:** Investigation, Formal analysis. **Clifford R. Jack:** Investigation, Formal analysis. **Prashanthi Vemuri:** Conceptualization, Methodology, Investigation, Formal analysis, Writing - original draft.

Acknowledgements

This work was supported by NIH grants R01 NS097495 (PI: Vemuri), R01 AG056366 (PI: Vemuri), U01 AG006786 (PI: Petersen), P50 AG016574 (PI: Petersen), R37 AG011378 (PI: Jack), R01 AG041851 (PIs: Jack and Knopman); R01 AG034676 (Rochester Epidemiology Project PI: Rocca); the Gerald and Henrietta Rauenhorst Foundation grant, the Millis Family, the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation, Alzheimer's Association (Zenith Fellows Award), Liston Award, Elsie and Marvin Dekelboum Family Foundation, Schuler Foundation, and Opus building NIH grant C06 RR018898. The data contained in the manuscript being submitted have not been previously published, have not been submitted elsewhere, and will not be submitted elsewhere while under consideration at Neurobiology of Aging. The study was approved by the Mayo Clinic and Olmsted Medical Center institutional review board, and written informed

consent was obtained from all participants. All authors have reviewed the contents of the manuscript being submitted, approved of its contents, and validated the accuracy of the data.The authors thank all the study participants and staff in the Mayo Clinic Study of Aging, Mayo Alzheimer's Disease Research Center, and Aging Dementia Imaging Research laboratory at the Mayo Clinic for making this study possible. The authors gratefully acknowledge the support of NVIDIA Corporation for the donation of the Quadro P5000 GPU used in this research.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.neurobiolaging.2020.09.005.

References

Al-Janabi, O.M., Brown, C.A., Bahrani, A.A., Abner, E.L., Barber, J.M., Gold, B.T., Jicha, G.A., 2018. Distinct white matter changes associated with cerebrospinal fluid amyloid-β1-42 and hypertension. J. Alzheimers Dis. 66, 1095–1104.

Andersson, J.L.R., Graham, M.S., Zsoldos, E., Sotiropoulos, S.N., 2016. Incorporating outlier detection and replacement into a non-parametric framework for movement and distortion correction of diffusion MR images. Neuroimage 141, 556–572.

Avants, B.B., Tustison, N.J., Song, G., Cook, P.A., Klein, A., Gee, J.C., 2011. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033–2044.

Berlot, R., Metzler-Baddeley, C., Jones, D.K., O'Sullivan, M.J., 2014. CSF contamination contributes to apparent microstructural alterations in mild cognitive impairment. Neuroimage 92, 27–35.

Bruscoli, M., Lovestone, S., 2004. Is MCI really just early dementia? A systematic review of conversion studies. Int. Psychogeriatr. 16, 129–140.

Catani, M., ffytche, D.H., 2005. The rises and falls of disconnection syndromes. Brain 128 (Pt 10), 2224–2239.

Chao, L.L., Decarli, C., Kriger, S., Truran, D., Zhang, Y., Laxamana, J., Weiner, M.W., 2013. Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One 8, e65175.

Chen, T.F., Lin, C.C., Chen, Y.F., Liu, H.M., Hua, M.S., Huang, Y.C., Chiu, M.J., 2009. Diffusion tensor changes in patients with amnesic mild cognitive impairment and various dementias. Psychiatry Res. 173, 15–21.

Concha, L., Gross, D.W., Beaulieu, C., 2005. Diffusion tensor tractography of the limbic system. AJNR Am. J. Neuroradiol. 26, 2267–2274.

Croall, I.D., Lohner, V., Moynihan, B., Khan, U., Hassan, A., O'Brien, J.T., Markus, H.S., 2017. Using DTI to assess white matter microstructure in cerebral small vessel disease (SVD) in multicentre studies. Clin. Sci. (Lond) 131, 1361–1373.

Elahi, S., Bachman, A.H., Lee, S.H., Sidtis, J.J., Ardekani, B.A., 2015. Corpus callosum atrophy rate in mild cognitive impairment and prodromal Alzheimer's disease. J. Alzheimers Dis. 45, 921–931.

Garyfallidis, E., Brett, M., Amirbekian, B., Rokem, A., van der Walt, S., Descoteaux, M., Nimmo-Smith, I., 2014. Dipy, a library for the analysis of diffusion MRI data. Front Neuroinform. 8, 8.

Gold, B.T., Zhu, Z., Brown, C.A., Andersen, A.H., LaDu, M.J., Tai, L., Smith, C.D., 2014. White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. Neurobiol. Aging 35, 2263–2271.

Graff-Radford, J., Arenaza-Urquijo, E.M., Knopman, D.S., Schwarz, C.G., Brown, R.D., Rabinstein, A.A., Vemuri, P., 2019. White matter hyperintensities: relationship to amyloid and tau burden. Brain 142, 2483–2491.

Jack Jr., C.R., Wiste, H.J., Weigand, S.D., Therneau, T.M., Lowe, V.J., Knopman, D.S., Petersen, R.C., 2017. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 13, 205–216.

Jacobs, H.I.L., Hedden, T., Schultz, A.P., Sepulcre, J., Perea, R.D., Amariglio, R.E., Johnson, K.A., 2018. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat. Neurosci. 21, 424–431.

Jones, D.K., Cercignani, M., 2010. Twenty-five pitfalls in the analysis of diffusion MRI data. NMR Biomed. 23, 803–820.

Kellner, E., Dhital, B., Kiselev, V.G., Reisert, M., 2016. Gibbs-ringing artifact removal based on local subvoxel-shifts. Magn. Reson. Med. 76, 1574–1581.

Knopman, D.S., Griswold, M.E., Lirette, S.T., Gottesman, R.F., Kantarci, K., Sharrett, A.R., Mosley Jr., T.H., 2015. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke 46, 433–440.

Koay, C.G., Ozarslan, E., Basser, P.J., 2009. A signal transformational framework for breaking the noise floor and its applications in MRI. J. Magn. Reson. 197, 108–119.

Lamar, M., Catani, M., Price, C.C., Heilman, K.M., Libon, D.J., 2008. The impact of region-specific leukoaraiosis on working memory deficits in dementia. Neuropsychologia 46, 2597–2601.

Lopresti, B.J., Klunk, W.E., Mathis, C.A., Hoge, J.A., Ziolko, S.K., Lu, X., Price, J.C., 2005. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 46, 1959–1972.

Metzler-Baddeley, C., O'Sullivan, M.J., Bells, S., Pasternak, O., Jones, D.K., 2012. How and how not to correct for CSF-contamination in diffusion MRI. Neuroimage 59, 1394–1403.

O'Sullivan, M., Summers, P.E., Jones, D.K., Jarosz, J.M., Williams, S.C., Markus, H.S., 2001. Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study. Neurology 57, 2307–2310.

Oishi, K., Faria, A., Jiang, H., Li, X., Akhter, K., Zhang, J., Mori, S., 2009. Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer's disease participants. Neuroimage 46, 486–499.

Papma, J.M., de Groot, M., de Koning, I., Mattace-Raso, F.U., van der Lugt, A., Vernooij, M.W., Smits, M., 2014. Cerebral small vessel disease affects white matter microstructure in mild cognitive impairment. Hum. Brain Mapp. 35, 2836–2851.

Petersen, R.C., 2009. Early diagnosis of Alzheimer's disease: is MCI too late? Curr. Alzheimer Res. 6, 324–330.

Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Winblad, B., 2001. Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985–1992.

Petersen, R.C., Roberts, R.O., Knopman, D.S., Geda, Y.E., Cha, R.H., Pankratz, V.S., Rocca, W.A., 2010. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 75, 889–897.

Power, M.C., Su, D., Wu, A., Reid, R.I., Jack, C.R., Knopman, D.S., Mosley, T.H., 2019. Association of white matter microstructural integrity with cognition and dementia. Neurobiol. Aging 83, 63–72.

Quigley, H., Colloby, S.J., O'Brien, J.T., 2011. PET imaging of brain amyloid in dementia: a review. Int. J. Geriatr. Psychiatry 26, 991–999.

Rabin, J.S., Perea, R.D., Buckley, R.F., Neal, T.E., Buckner, R.L., Johnson, K.A., Hedden, T., 2019. Global white matter diffusion characteristics predict longitudinal cognitive change independently of amyloid status in clinically normal older adults. Cereb. Cortex 29, 1251–1262.

Reid, R.I., Nedelska, Z., Schwarz, C.G., Ward, C., Jack, C.R., 2018. Diffusion Specific Segmentation: Skull Stripping with Diffusion MRI Data Alone. In: Kaden, E., Ning, L., Tax, C., Veraart, J. (Eds.), F. G. Springer, Cham.

Rieckmann, A., Van Dijk, K.R., Sperling, R.A., Johnson, K.A., Buckner, R.L., Hedden, T., 2016. Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiol. Aging 42, 177–188.

Roberts, R.O., Geda, Y.E., Knopman, D.S., Cha, R.H., Pankratz, V.S., Boeve, B.F., Rocca, W.A., 2008. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58–69.

Rocca, W.A., Yawn, B.P., St Sauver, J.L., Grossardt, B.R., Melton 3rd., L.J., 2012. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin. Proc. 87, 1202–1213.

Schwarz, C.G., Gunter, J.L., Wiste, H.J., Przybelski, S.A., Weigand, S.D., Ward, C.P., Jack Jr., C.R., 2016. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. Neuroimage Clin. 11, 802–812.

St Sauver, J.L., Grossardt, B.R., Yawn, B.P., Melton 3rd, L.J., Pankratz, J.J., Brue, S.M., Rocca, W.A., 2012. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int. J. Epidemiol. 41, 1614–1624.

Thomann, P.A., Wustenberg, T., Pantel, J., Essig, M., Schroder, J., 2006. Structural changes of the corpus callosum in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21, 215–220.

Tu, M.C., Lo, C.P., Huang, C.F., Hsu, Y.H., Huang, W.H., Deng, J.F., Lee, Y.C., 2017. Effectiveness of diffusion tensor imaging in differentiating early-stage subcortical ischemic vascular disease, Alzheimer's disease and normal ageing. PLoS One 12, e0175143.

Tuladhar, A.M., van Norden, A.G., de Laat, K.F., Zwiers, M.P., van Dijk, E.J., Norris, D.G., de Leeuw, F.E., 2015. White matter integrity in small vessel disease is related to cognition. Neuroimage Clin. 7, 518–524.

Tullberg, M., Fletcher, E., DeCarli, C., Mungas, D., Reed, B.R., Harvey, D.J., Jagust, W.J., 2004. White matter lesions impair frontal lobe function regardless of their location. Neurology 63, 246–253.

Vemuri, P., Lesnick, T.G., Przybelski, S.A., Graff-Radford, J., Reid, R.I., Lowe, V.J., Jack Jr., C.R., 2018. Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Ann. Neurol. 84, 705–716.

Vemuri, P., Lesnick, T.G., Przybelski, S.A., Machulda, M., Knopman, D.S., Mielke, M.M., Jack Jr., C.R., 2014. Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA Neurol. 71, 1017–1024.

Veraart, J., Novikov, D.S., Christiaens, D., Ades-Aron, B., Sijbers, J., Fieremans, E., 2016. Denoising of diffusion MRI using random matrix theory. Neuroimage 142, 394–406.

Wang, H., Su, M.Y., 2006. Regional pattern of increased water diffusivity in hippocampus and corpus callosum in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 22, 223–229.

Wang, L., Goldstein, F.C., Veledar, E., Levey, A.I., Lah, J.J., Meltzer, C.C., Mao, H., 2009. Alterations in cortical thickness and white matter integrity in mild cognitive impairment measured by whole-brain cortical thickness mapping and diffusion tensor imaging. AJNR Am. J. Neuroradiol. 30, 893–899.

Wassenaar, T.M., Yaffe, K., van der Werf, Y.D., Sexton, C.E., 2019. Associations between modifiable risk factors and white matter of the aging brain: insights from diffusion tensor imaging studies. Neurobiol. Aging 80, 56–70.

Weaver, N.A., Doeven, T., Barkhof, F., Biesbroek, J.M., Groeneveld, O.N., Kuijf, H.J., Biessels, G.J., 2019. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiol. Aging 84, 225–234.

Williams, O.A., Zeestraten, E.A., Benjamin, P., Lambert, C., Lawrence, A.J., Mackinnon, A.D., Barrick, T.R., 2017. Diffusion tensor image segmentation of the cerebrum provides a single measure of cerebral small vessel disease severity related to cognitive change. Neuroimage Clin. 16, 330–342.

Zhu, M., Gao, W., Wang, X., Shi, C., Lin, Z., 2012. Progression of corpus callosum atrophy in early stage of Alzheimer's disease: MRI based study. Acad. Radiol. 19, 512–517.